Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00022620
Status:
COMPLETED
Last Update Posted:
2012-09-24
First Post:
2001-08-10
Brief Title:
Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
European Organisation for Research and Treatment of Cancer - EORTC
Study Overview
Official Title:
Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma UPSC
Status:
COMPLETED
Status Verified Date:
2012-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of paclitaxel in treating patients who have refractory or recurrent endometrial cancer
PURPOSE Phase II trial to study the effectiveness of paclitaxel in treating patients who have refractory or recurrent endometrial cancer
Detailed Description:
OBJECTIVES
Determine the therapeutic activity of paclitaxel in patients with refractory or recurrent endometrial papillary carcinoma
Determine the objective response and duration of response in patients treated with this regimen
Determine the acute side effects of this regimen in these patients
OUTLINE This is a multicenter study
Patients receive paclitaxel IV over 3 hours on day 1 Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity
Patients are followed every 12 weeks
PROJECTED ACCRUAL Approximately 16-29 patients will be accrued for this study
Determine the therapeutic activity of paclitaxel in patients with refractory or recurrent endometrial papillary carcinoma
Determine the objective response and duration of response in patients treated with this regimen
Determine the acute side effects of this regimen in these patients
OUTLINE This is a multicenter study
Patients receive paclitaxel IV over 3 hours on day 1 Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity
Patients are followed every 12 weeks
PROJECTED ACCRUAL Approximately 16-29 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EORTC-55961 | None | None | None |